The drumbeat of innovation in the heart valves space continues as companies pursue next-generation devices for easier implantation, to improve durability and to treat younger patients. Even though ...

South San Francisco-based Trex Bio Inc. priced its IPO of about 8.3 million shares at $14 per share for about $116.7 million to finance efforts taking aim at a pair of targets hardly unfamiliar to the ...

Several initiatives the U.S. Department of Health and Human Services (HHS) announced Oct. 8 continue to shift the government’s vaccine focus from disease prevention to vaccine harm. Strengthening “how ...

Neurizon Therapeutics Ltd. has advanced NUZ-001 (monepantel) from a 12-patient proof-of-concept study into a fully enrolled, ...

In the last five years, public markets in Europe have been a no-go area for biotechs, and for U.K. companies the situation is dire, with the way barred to new entrants and a lack of liquidity leading ...

Ono Pharmaceutical Co. Ltd. is paying $100 million up front to gain select Asian rights to Biohaven Ltd.’s small-molecule IgG degrader portfolio, including in Japan, South Korea and Taiwan, as it ...

Vinci Pharmaceuticals Inc. has closed a series A financing round raising over $8 million as the company advances development of its Epiplant delivery platform.

Despite their clinical success, real-world data suggest that GLP-1 receptor agonists may be limited by challenges, driving interest in complementary mechanisms that target the underlying metabolic ...

Tsinghua University has patented new antibody-drug conjugates consisting of a monoclonal antibody targeting immune checkpoint and/or tumor antigen molecule covalently bound to a small molecule ...

Persistent mycobacterial infections may depend on senescent macrophages that provide a long-term intracellular refuge to ...

Ningbo Jiefu Biotechnology Co. Ltd. has identified new epidermal growth factor receptor (EGFR; ERBB1; HER1) inhibitors and EGFR protein/nucleic acid degraders potentially useful for the treatment of ...

Shanghaitech University has synthesized thiadiazole derivatives acting as muscarinic acetylcholine M4 receptor agonists reported to be useful for the treatment of schizophrenia and Alzheimer’s disease ...